Literature DB >> 26637902

Loss of ARID1A, ARID1B, and ARID2 Expression During Progression of Gastric Cancer.

Tatsuya Aso1, Hiroshi Uozaki2, Shigeki Morita1, Arisa Kumagai1, Masato Watanabe1.   

Abstract

BACKGROUND/AIM: Gastric cancer is a common cancer worldwide. Chromatin remodeling complexes have emerged as tumor suppressors and include AT-rich interaction domain-containing proteins (ARIDs) 1A, 1B, and 2. We examined their expression and clarified their roles in gastric carcinogenesis.
MATERIALS AND METHODS: The expression of ARIDs was studied by immunohistochemistry in 469 gastric carcinoma and 47 adenoma samples and was analyzed according to clinicopathological factors.
RESULTS: Low expression rates of ARID1A, 1B, and 2 in gastric carcinoma were 20%, 10%, and 15% respectively. ARIDs are correlated to each other. Low expression of ARID1A was related to advanced tumor and vessel infiltration. Loss of ARID1B and ARID2 was also related to tumor progression, but their relationship was weaker than that of ARID1A.
CONCLUSION: ARID1A is the strongest tumor suppressor in gastric carcinogenesis among ARIDs. Their aberration might be caused by shared mechanisms such as mutation and methylation. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  AT-rich interactive domain-containing protein; Gastric cancer; carcinogenesis; chromatin remodeling factor; immunohistochemistry

Mesh:

Substances:

Year:  2015        PMID: 26637902

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

1.  Low MLL2 Protein Expression Is Associated With Fibrosis in Early Stage Gastric Cancer.

Authors:  Satoe Numakura; Hiroshi Uozaki
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

2.  Whole-exome sequencing to identify somatic mutations in peritoneal metastatic gastric adenocarcinoma: A preliminary study.

Authors:  Hao Liu; Fengping Li; Yu Zhu; Tingting Li; Haipeng Huang; Tian Lin; Yanfeng Hu; Xiaolong Qi; Jiang Yu; Guoxin Li
Journal:  Oncotarget       Date:  2016-07-12

Review 3.  Characterization of potential driver mutations involved in human breast cancer by computational approaches.

Authors:  Barani Kumar Rajendran; Chu-Xia Deng
Journal:  Oncotarget       Date:  2017-07-25

Review 4.  Unique characteristics of ARID1A mutation and protein level in gastric and colorectal cancer: A meta-analysis.

Authors:  Young-Sik Kim; Hoiseon Jeong; Jung-Woo Choi; Hwa Eun Oh; Ju-Han Lee
Journal:  Saudi J Gastroenterol       Date:  2017 Sep-Oct       Impact factor: 2.485

5.  A potentially functional variant of ARID1B interacts with physical activity in association with risk of hepatocellular carcinoma.

Authors:  Li Liu; Nana Tian; Chengyu Zhou; Xinqi Lin; Weibiao Lv; Zhifeng Lin; Zibo Lin; Yongfen Qi; Yi Yang; Sidong Chen; Xinfa Yu; Yanhui Gao
Journal:  Oncotarget       Date:  2017-05-09

6.  HBx protein-mediated ATOH1 downregulation suppresses ARID2 expression and promotes hepatocellular carcinoma.

Authors:  Qingzhu Gao; Kai Wang; Ke Chen; Li Liang; Yaqiu Zheng; Yunzhi Zhang; Jin Xiang; Ni Tang
Journal:  Cancer Sci       Date:  2017-06-14       Impact factor: 6.716

Review 7.  Targeting Loss of Heterozygosity: A Novel Paradigm for Cancer Therapy.

Authors:  Xiaonan Zhang; Tobias Sjöblom
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-13

8.  Expression and prognostic values of ARID family members in breast cancer.

Authors:  Jinfeng Zhang; Siyu Hou; Zilong You; Guozheng Li; Shouping Xu; Xianyong Li; Xianyu Zhang; Bo Lei; Da Pang
Journal:  Aging (Albany NY)       Date:  2021-02-11       Impact factor: 5.682

9.  Precision medicine and actionable alterations in lung cancer: A single institution experience.

Authors:  Isa Mambetsariev; Yingyu Wang; Chen Chen; Sorena Nadaf; Rebecca Pharaon; Jeremy Fricke; Idoroenyi Amanam; Arya Amini; Andrea Bild; Peiguo Chu; Loretta Erhunmwunsee; Jae Kim; Janet Munu; Raju Pillai; Dan Raz; Sagus Sampath; Lalit Vora; Fang Qiu; Lynette Smith; Surinder K Batra; Erminia Massarelli; Marianna Koczywas; Karen Reckamp; Ravi Salgia
Journal:  PLoS One       Date:  2020-02-11       Impact factor: 3.240

10.  AT-rich interactive domain1A determines sensitivity to oxaliplatin in gastric cancer cells.

Authors:  Qing Liu; Qing-Qing Weng; Song-Fei Shen; Tao Jiang; Zhang-Chi Pan; Meng-Xin Lin; Yan-Qin Lan; Yao Wang; Qiang Chen; Chun-Mei Shi
Journal:  Transl Cancer Res       Date:  2020-12       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.